Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) dropped 9.2% on Tuesday . The company traded as low as $5.81 and last traded at $5.67. Approximately 28,337 shares changed hands during mid-day trading, an increase of 1% from the average daily volume of 28,037 shares. The stock had previously closed at $6.24.
Analysts Set New Price Targets
IVA has been the topic of several analyst reports. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 target price on shares of Inventiva in a report on Tuesday, September 30th. HC Wainwright started coverage on Inventiva in a research report on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research note on Saturday, September 27th. Piper Sandler initiated coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price objective for the company. Finally, Guggenheim lifted their price target on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Inventiva currently has a consensus rating of "Moderate Buy" and an average target price of $15.57.
View Our Latest Report on IVA
Inventiva Stock Performance
The firm has a 50-day moving average of $4.96 and a 200 day moving average of $3.88.
Institutional Investors Weigh In On Inventiva
An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company's stock.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
